Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Elmex Gel Efficacy in Preventing White Spot Lesions
This study is currently recruiting participants.
Verified by Hadassah Medical Organization, December 2005
Sponsors and Collaborators: Hadassah Medical Organization
Gaba International AG
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00268138
  Purpose

the objective of this phase IV study: to establish the efficacy of elmex gel with a fluoride concentration of 1.25% compared with placebo by determining prevention of white spot lesions in patients wearing fixed orthodontic appliances.


Condition Intervention Phase
Dental Caries
Drug: elmex gel
Phase IV

Drug Information available for: Fluoride Sodium fluoride Stannous fluoride Elmex
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • time and frequency of visually detected WSL (white spot lesions) [ Time Frame: 3 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • mineral loss according to QLF readings [ Time Frame: 3 month ] [ Designated as safety issue: No ]
  • Frequency and chronoloy of WSL [ Time Frame: 3 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 314
Study Start Date: April 2006
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: elmex gel
    elmex gel once a week
Detailed Description:

314 healthy subjects undergoing orthodontic treatment will be examined. follow up will take place from bonding the appliance till debonding, at least 12 months and no more than 30 months.

tooth brushing with product (test product or control) once per week during the entire study.

4 times a year additional tray application of test product or control. subjects wiil clean their teeth with the toothpaste they usually use during the entire study.

toothbrush and a sandglass will be provided every 6 weeks

  Eligibility

Ages Eligible for Study:   10 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • treatment plan: minimum of 10 teeth to be bonded labially at least 10 years old
  • written declaration of informed consent

Exclusion Criteria:

  • known allergy to components of test products
  • handicapped patients who have difficulties brushing their teeth
  • pathological desquamation changes
  • known pregnancy, breast feeding
  • eating disorders
  • disease that effect dental hard tissue
  • participation in another clinical trial either currently or within the lase 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00268138

Contacts
Contact: Andrea Engl, Dr. ++41614156056 a.engl@gaba.com

Locations
Germany
Charite University Recruiting
Berlin, Germany, D-13353
Contact: Paul-Georg Jost-Brinkmann, Prof     ++4930450562532     paul-g.jost-brinkmann@charite.de    
Israel
Hadassah Medical Organization, Jerusalem, Israel Recruiting
Jerusalem, Israel, 91120
Contact: Arik tzukert, DMD     00 972 2 6776095     arik@hadassah.org.il    
Contact: Hadas Lemberg, Phd     00 972 2 6777572     lhadas@hadassah.org.il    
Principal Investigator: Meir Redlich, DMD PhD            
Sponsors and Collaborators
Hadassah Medical Organization
Gaba International AG
Investigators
Principal Investigator: Meir Redlich, DMD PhD Hadassah Medical Center, Dept of Orthodontics
Principal Investigator: Paul George Jost-Brinkmann, Prof Charite - Berlin, Dept of Orthodontics, Center of Dentistry
  More Information

Responsible Party: Hadassah ( Dr Meir Redlich )
Study ID Numbers: 123456-HMO-CTIL
Study First Received: December 21, 2005
Last Updated: June 29, 2008
ClinicalTrials.gov Identifier: NCT00268138  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
amine fluoride
white spot lesions
qlf

Study placed in the following topic categories:
Tooth Diseases
Stomatognathic Diseases
Fluorides
Dental Caries

Additional relevant MeSH terms:
Tooth Demineralization

ClinicalTrials.gov processed this record on February 06, 2009